Amicus Therapeutics, Inc. (FOLD)
FOLD moved a median of +0.04% 30 minutes after news, and +0.07% by the close. How FOLD actually reacts to news — the realized, point-in-time move the market made, measured across 382 labeled events over the last three years with zero look-ahead.
FOLD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.15% | 40% | 324 |
| 30-min | +0.04% | 51% | 324 |
| 60-min | +0.05% | 54% | 324 |
| to close | +0.07% | 51% | 323 |
| Middle 50% of FOLD reactions | -0.65% to +0.80% |
|---|---|
| Median reaction (30-min) | +0.04% |
| Measured reactions | 382 |
Half of all Amicus Therapeutics, Inc. news events land between -0.65% and +0.80% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How FOLD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 18 | -0.58% | 33% | -0.53% |
| Analyst downgrades | 26 | -0.04% | 42% | -0.23% |
| Rating reiterations | 41 | -0.17% | 39% | -0.35% |
| Price-target raises | 10 | -0.07% | 40% | -0.94% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how FOLD ranks against every other measured name →
That’s how FOLD usually reacts — get an email when it moves on news →Email me when FOLD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to FOLD's baseline. Nothing else.
Recent FOLD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G AMICUS THERAPEUTICS, | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT AMICUS THERAPEUTICS, | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K AMICUS THERAPEUTICS, For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM AMICUS THERAPEUTICS, | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form POSASR AMICUS THERAPEUTICS, | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS AMICUS THERAPEUTICS, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K AMICUS THERAPEUTICS, For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | +0.04% | +0.00% | |
| Form 8-K AMICUS THERAPEUTICS, For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -0.07% | -0.14% | |
| Form DEFA14A AMICUS THERAPEUTICS, | SEC filing · Form DEFA14A | SEC EDGAR | -0.04% | +0.07% | |
| Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates | Press release | GlobeNewswire | +0.14% | +0.21% | |
| Form 10-K AMICUS THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.14% | +0.21% | |
| Form 8-K AMICUS THERAPEUTICS, For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | +0.21% | |
| Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026 | Press release | GlobeNewswire | -0.04% | -0.07% | |
| Form DEFM14A AMICUS THERAPEUTICS, | SEC filing · Form DEFM14A | SEC EDGAR | +0.04% | +0.00% | |
| Form 8-K AMICUS THERAPEUTICS, For: Jan 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.07% | |
| Form DEFA14A AMICUS THERAPEUTICS, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +0.07% | |
| FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders | Press release | Business Wire | +0.00% | -0.07% | |
| Form PREM14A AMICUS THERAPEUTICS, For: Jan 21 | SEC filing · Form PREM14A | SEC EDGAR | -0.17% | -0.28% | |
| Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights | Press release | PR Newswire | +0.00% | +0.04% | |
| FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders | Press release | Business Wire | +0.11% | +0.07% | |
| Form 8-K AMICUS THERAPEUTICS, For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | +0.11% | +0.07% | |
| Form DEFA14A AMICUS THERAPEUTICS, | SEC filing · Form DEFA14A | SEC EDGAR | +0.11% | +0.07% | |
| Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates | Press release | GlobeNewswire | +2.64% | -0.99% | |
| Form 10-Q AMICUS THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.21% | +1.55% | |
| Form 8-K AMICUS THERAPEUTICS, For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +2.64% | -0.99% | |
| Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 | Press release | GlobeNewswire | +0.31% | +1.69% | |
| Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025 | Press release | GlobeNewswire | -1.05% | -0.82% | |
| New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM | Press release | GlobeNewswire | +0.56% | -0.38% | |
| Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 | Press release | GlobeNewswire | +0.00% | -1.04% | |
| Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates | Press release | GlobeNewswire | -0.95% | -4.77% | |
| Form 10-Q AMICUS THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.84% | +6.04% | |
| Form 8-K AMICUS THERAPEUTICS, For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -0.95% | -4.77% | |
| Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 | Press release | GlobeNewswire | +0.32% | +0.83% | |
| SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm | Press release | PR Newswire | -2.02% | -2.17% | |
| Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan | Press release | GlobeNewswire | -2.54% | -0.70% | |
| Form 8-K AMICUS THERAPEUTICS, For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +0.50% | +2.16% | |
| Form S-8 AMICUS THERAPEUTICS, | SEC filing · Form S-8 | SEC EDGAR | +0.50% | +2.16% | |
| New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve | Press release | GlobeNewswire | -0.16% | +1.79% | |
| Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 | Press release | GlobeNewswire | -1.62% | -1.78% | |
| Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference | Press release | GlobeNewswire | +0.32% | -2.40% | |
| Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates | Press release | GlobeNewswire | +4.01% | +1.21% | |
| Form 10-Q AMICUS THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.22% | -0.30% | |
| Form 8-K AMICUS THERAPEUTICS, For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | +4.01% | +1.21% | |
| Form 8-K AMICUS THERAPEUTICS, For: May 01 | SEC filing · Form 8-K | SEC EDGAR | +4.01% | +1.21% | |
| Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States | Press release | GlobeNewswire | +4.01% | +1.21% | |
| Form ARS AMICUS THERAPEUTICS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.70% | +2.94% | |
| Form DEF 14A AMICUS THERAPEUTICS, For: Jun 05 | SEC filing · Form DEF | SEC EDGAR | -0.70% | +2.94% | |
| Form DEFA14A AMICUS THERAPEUTICS, | SEC filing · Form DEFA14A | SEC EDGAR | -0.70% | +2.94% | |
| Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 | Press release | GlobeNewswire | -0.15% | -0.89% | |
| AMICUS STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Investors to Contact the Firm | Press release | GlobeNewswire | -1.72% | -1.51% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the FOLD section they belong to.
Where else FOLD is measured.
FOLD earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ARADIGM CORP COMMON STOCK (ARDM) | 384 | 0.00% | 39% |
| HISTOGENICS CORP COMMON (HSGX) | 383 | -0.30% | 35% |
| CORIUM INTL (CORI) | 380 | 0.00% | 46% |
| PROTEON THERAPEUTICS (PRTO) | 380 | 0.00% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Amicus Therapeutics, Inc.'s median reaction calculated?
Every labeled FOLD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 382 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of FOLD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does FOLD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.